ACAD vs MKTX · P/E 15, rev $957.8M vs P/E 13, rev $817.1M
ACADIA Pharmaceuticals Inc (ACAD) versus MarketAxess Holdings Inc (MKTX) — a side-by-side from cached financials, not a winner call.
ACADIA Pharmaceuticals Inc (ACAD) is a biotechnology company listed on US.
MarketAxess Holdings Inc (MKTX) is a capital markets company listed on US.
Latest reported ACAD revenue for 2024-12-31 was $957.8M. Net income was $226.5M. Revenue was up 314.6% from 2023-12-31 to 2024-12-31. ACAD currently screens at market cap $3.51B and trailing P/E 15.3.
Latest reported MKTX revenue for 2024-12-31 was $817.1M. Net income was $274.2M. Revenue was up 8.6% from 2023-12-31 to 2024-12-31. MKTX currently screens at market cap $4.00B and trailing P/E 13.3.
ACAD currently screens at market cap $3.51B and trailing P/E 15.3. MKTX currently screens at market cap $4.00B and trailing P/E 13.3.
Not investment advice. Open the ACAD and MKTX stock pages for the full models.
Not investment advice.